Microbes and microbial effector molecules in treatment of inflammatory disorders

Immunological Reviews

Volumn 245, Issue 1, 2012, Pages 27-44

  Kelly, Denise ^a   Delday, Margaret I ^a   Mulder, Imke ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Bacteroides; Commensals; Firmicutes; Inflammatory diseases; Molecular effectors

Indexed keywords

BACTERIAL ANTIGEN; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; BACTEROIDES; CELL POPULATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; COMMENSAL; CROHN DISEASE; DENDRITIC CELL; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; EPITHELIUM CELL; FIRMICUTES; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; MICROBIAL COLONIZATION; MICROBIAL DIVERSITY; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; ULCERATIVE COLITIS;

ANIMALS; ANTIGENS, BACTERIAL; AUTOIMMUNITY; BACTEROIDETES; BIOLOGICAL THERAPY; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INTESTINAL DISEASES; INTESTINES; PROBIOTICS; SYMBIOSIS; T-LYMPHOCYTES;

EID: 83655191579     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01079.x     Document Type: Review

References (190)

1. Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-1638.
2. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
3. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005;102:11070-11075.
4. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006;124:837-848.
5. Manichanh C, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006;55:205-211.
6. Arumugam M, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-180.
7. Koenig JE, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 2011;108(Suppl):4578-4585.
8. Elinav E, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145:745-757.
9. Dominguez-Bello MG, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010;107:11971-11975.
10. Mulder IE, et al. Environmentally-acquired bacteria influence microbial diversity and natural innate immune responses at gut surfaces. BMC Biol 2009;7:79.
11. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011;140:1713-1719.
12. Benson AK, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 2010;107:18933-18938.
13. Caporaso JG, et al. Moving pictures of the human microbiome. Genome Biol 2011;12:R50.
14. Walter J, Ley RE. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011; 65:411-429. in press.
15. Xu J, et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 2003;299:2074-2076.
16. Samuel BS, et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut. Proc Natl Acad Sci USA 2007;104:10643-10648.
17. Turroni F, et al. Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. Proc Natl Acad Sci USA 2010;107:19514-19519.
18. Motherway MO, et al. Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci USA 2011;108:11217-11222.
19. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007;449:804-810.
20. Human Microbiome Jumpstart Reference Strains Consortium, et al. A catalog of reference genomes from the human microbiome. Science 2010;328:994-999.
21. Goodman AL, et al. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 2009;6:279-289.
22. Benjdia A, Martens EC, Gordon JI, Berteau O. Sulfatases and a radical S-adenosyl-l-methionine (AdoMet) enzyme are key for mucosal foraging and fitness of the prominent human gut symbiont, Bacteroides thetaiotaomicron. J Biol Chem 2011;286: 25973-25982.
23. Koropatkin N, Martens EC, Gordon JI, Smith TJ. Structure of a SusD homologue, BT1043, involved in mucin O-glycan utilization in a prominent human gut symbiont. Biochemistry 2009;48:1532-1542.
24. Turnbaugh PJ, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480-484.
25. Ivanov II, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-349.
26. Gaboriau-Routhiau V, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009;31:677-689.
27. Atarashi K, Tanoue T, Umesaki Y, Honda K. Regulation of Th17 cell differentiation by intestinal commensal bacteria. Benef Microbes 2010;1:327-334.
28. Frank DN, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:179-184.
29. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7:887-894.
30. Lyte M. The microbial organ in the gut as a driver of homeostasis and disease. Med Hypotheses 2010;74:634-638.
31. Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res 2011;343:23-32.
32. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. Bioessays 2011;33:574-581.
33. Bercik P, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011;141:599-609.
34. Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun 2010;24:9-16.
35. Bravo JA, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011;38:16050-16055.
36. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330:1768-1773.
37. Relman DA. 'Til death do us part': coming to terms with symbiotic relationships. Forward. Nat Rev Microbiol 2008;6:721-724.
38. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323.
39. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279-290.
40. Serino M, Luche E, Chabo C, Amar J, Burcelin R. Intestinal microflora and metabolic diseases. Diabetes Metab 2009;35:262-272.
41. Wen L, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008;455:1109-1113.
42. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007;44:256-262.
43. Koren O, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011;108(Suppl):4592-4598.
44. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011;108(Suppl):4615-4622.
45. Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J Immunol 2004;172:1118-1124.
46. Reading NC, Kasper DL. The starting lineup: key microbial players in intestinal immunity and homeostasis. Front Microbiol 2011;2:148.
47. Stecher B, et al. Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog 2010;6:e1000711.
48. Jarchum I, Pamer EG. Regulation of innate and adaptive immunity by the commensal microbiota. Curr Opin Immunol 2011;23:353-360.
49. Geuking MB, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011;34:794-806.
50. Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-498.
51. Atarashi K, Tanoue T, Honda K. Induction of lamina propria Th17 cells by intestinal commensal bacteria. Vaccine 2010;28:8036-8038.
52. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010; 107: 12204-12209.
53. Kelly D, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5:104-112.
54. Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N, Heyman M. Mechanisms involved in alleviation of intestinal inflammation by Bifidobacterium breve soluble factors. PLoS ONE 2009;4:e5184.
55. Kumar A, et al. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 2007;26:4457-4466.
56. Lakhdari O, et al. Identification of NF-kappaB modulation capabilities within human intestinal commensal bacteria. J Biomed Biotechnol 2011;2011:282356.
57. Biswas A, et al. Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. Eur J Immunol 2011;41:182-194.
58. Mondot S, et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis 2011;17:185-192.
59. Martin HM, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004;127:80-93.
60. Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669-675.
61. Martinez-Medina M, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009;15:872-882.
62. Brandtzaeg P. The gut as communicator between environment and host: immunological consequences. Eur J Pharmacol 2011; in press.
63. Karczewski J, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010;298:G851-G859.
64. Brandtzaeg P. Homeostatic impact of indigenous microbiota and secretory immunity. Benef Microbes 2010;1:211-227.
65. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008;1:11-22.
66. Suzuki K, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA 2004; 101:1981-1986.
67. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008;105:15064-15069.
68. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011;108(Suppl):4659-4665.
69. Lopez-Boado YS, Wilson CL, Hooper LV, Gordon JI, Hultgren SJ, Parks WC. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J Cell Biol 2000;148:1305-1315.
70. Meyer-Hoffert U, et al. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 2008;57:764-771.
71. Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria. Curr Opin Microbiol 2011;14:106-114.
72. Slack E, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009;325:617-620.
73. Salzman NH, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010;11:76-83.
74. Huang JY, Lee SM, Mazmanian SK. The human commensal Bacteroides fragilis binds intestinal mucin. Anaerobe 2011;4:137-141.
75. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Muller M, de Vos WM. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2011;2:166.
76. Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes 2011;2:99-104.
77. Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
78. Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology 2005;115:153-162.
79. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010;16:1583-1597.
80. Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol 2005;42:887-893.
81. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-144.
82. Hsu D, et al. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 2010; 90:1295-1305.
83. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
84. Ey B, Eyking A, Gerken G, Podolsky DK, Cario E. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 2009;284:22332-22343.
85. Asquith M, Powrie F. An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 2010;207:1573-1577.
86. Lee EG, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350-2354.
87. van Baarlen P, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA 2011;108(Suppl):4562-4569.
88. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-12486.
89. Chassin C, et al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe 2010;8:358-368.
90. Bansal T, Alaniz RC, Wood TK, Jayaraman A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci USA 2010;107:228-233.
91. Ivison SM, et al. The stress signal extracellular ATP modulates antiflagellin immune responses in intestinal epithelial cells. Inflamm Bowel Dis 2011;17:319-333.
92. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
93. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl):S81-S96.
94. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
95. Zaph C, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007;446:552-556.
96. Nenci A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-561.
97. Eckmann L, et al. Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci USA 2008;105:15058-15063.
98. Vossenkamper A, Macdonald TT, Marches O. Always one step ahead: how pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system. J Inflamm (Lond) 2011;8:11.
99. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol 2010;10:735-744.
100. Lotz M, Gutle D, Walther S, Menard S, Bogdan C, Hornef MW. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med 2006;203:973-984.
101. Neish AS, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-1563.
102. Collier-Hyams LS, Sloane V, Batten BC, Neish AS. Cutting edge: bacterial modulation of epithelial signaling via changes in neddylation of cullin-1. J Immunol 2005; 175:4194-4198.
103. Lakhdari O, et al. Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-kappaB modulation in the human gut. PLoS ONE 2010;5:e13092.
104. Tseng TT, Tyler BM, Setubal JC. Protein secretion systems in bacterial-host associations, and their description in the Gene Ontology. BMC Microbiol 2009;9(Suppl):S2.
105. Jani AJ, Cotter PA. Type VI secretion: not just for pathogenesis anymore. Cell Host Microbe 2010;8:2-6.
106. Chow J, Mazmanian SK. A pathobiont of the microbiota balances host colonization and intestinal inflammation. Cell Host Microbe 2010;7:265-276.
107. Coats SR, et al. The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria. Infect Immun 2011;79:203-210.
108. Kaiser P, Hardt WD. Salmonella Typhimurium diarrhea: switching the mucosal epithelium from homeostasis to defense. Curr Opin Immunol 2011;4:456-463.
109. Scott CL, Aumeunier AM, Mowat AM. Intestinal CD103(+) DCs: master regulators of tolerance? Trends Immunol 2011;9:412-419.
110. Schulz O, et al. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical DC functions. J Exp Med 2009;206:3101-3114.
111. Mucida D, et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 2009;30:471-472; author reply 472-473.
112. Hadis U, et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 2011;34:237-246.
113. Jarry A, Bossard C, Sarrabayrouse G, Mosnier JF, Laboisse CL. Loss of interleukin-10 or transforming growth factor-beta signaling in the human colon initiates a T-Helper 1 response via distinct pathways. Gastroenterology 2011; in press.
114. Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007;19:409-417.
115. Round JL, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011;332:974-977.
116. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140:845-858.
117. Kinjo Y, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-525.
118. Mattner J, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-529.
119. Wei B, et al. Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J Immunol 2010;184:1218-1226.
120. Hapfelmeier S, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 2010;328:1705-1709.
121. Melmed G, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170:1406-1415.
122. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004;126:1054-1070.
123. Grangette C, et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 2005;102:10321-10326.
124. Mohamadzadeh M, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA 2011;108(Suppl):4623-4630.
125. Wang S, et al. MyD88-dependent TLR1/2 signals educate DCs with gut-specific imprinting properties. J Immunol 2011;187:141-150.
126. Boulard O, Asquith MJ, Powrie F, Maloy KJ. TLR2-independent induction and regulation of chronic intestinal inflammation. Eur J Immunol 2010;40:516-524.
127. Mowat AM. Does TLR2 regulate intestinal inflammation? Eur J Immunol 2010;40:318-320.
128. Lillehoj EP, Kim BT, Kim KC. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am J Physiol Lung Cell Mol Physiol 2002;282:L751-L756.
129. Lodes MJ, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296-1306.
130. Hayashi F, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
131. Mizel SB, West AP, Hantgan RR. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem 2003;278:23624-23629.
132. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011;477:592-595.
133. Mizel SB, Snipes JA. Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem 2002;277:22414-22420.
134. Lee SK, Stack A, Katzowitsch E, Aizawa SI, Suerbaum S, Josenhans C. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003;5:1345-1356.
135. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;189:1914-1920.
136. Andersen-Nissen E, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci USA 2005;102:9247-9252.
137. Jarchum I, Liu M, Lipuma L, Pamer EG. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 2011;79:1498-1503.
138. Vijay-Kumar M, et al. Flagellin suppresses epithelial apoptosis and limits disease during enteric infection. Am J Pathol 2006;169:1686-1700.
139. Letran SE, Lee SJ, Atif SM, Uematsu S, Akira S, McSorley SJ. TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunity. Eur J Immunol 2011;41:29-38.
140. Andersen-Nissen E, et al. Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 2007;178:4717-4720.
141. Vijay-Kumar M, et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007;117:3909-3921.
142. Bates JT, Uematsu S, Akira S, Mizel SB. Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol 2009;182:7539-7547.
143. Letran SE, et al. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. J Immunol 2011;186:5406-5412.
144. Duck LW, et al. Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm Bowel Dis 2007;13:1191-1201.
145. Stecher B, Hapfelmeier S, Muller C, Kremer M, Stallmach T, Hardt WD. Flagella and chemotaxis are required for efficient induction of Salmonella enterica serovar Typhimurium colitis in streptomycin-pretreated mice. Infect Immun 2004;72:4138-4150.
146. Honko AN, Mizel SB. Effects of flagellin on innate and adaptive immunity. Immunol Res 2005;33:83-101.
147. Bambou JC, et al. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 2004;279:42984-42992.
148. Gewirtz AT, et al. Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response. J Clin Invest 2001;107:99-109.
149. Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis 2008;14:1051-1060.
150. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
151. Kreisman LS, Cobb BA. Glycoantigens induce human peripheral Tr1 cell differentiation with gut-homing specialization. J Biol Chem 2011;286:8810-8818.
152. Sharpe SW, Kuehn MJ, Mason KM. Elicitation of epithelial-derived immune effectors by outer membrane vesicles of nontypeable Haemophilus influenzae. Infect Immun 2011;11:4361-4369.
153. Unal CM, Schaar V, Riesbeck K. Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol 2011;33:395-408.
154. Kverka M, et al. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol 2011;163:250-259.
155. Hall JA, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29:637-649.
156. Jensen GS, Benson KF, Carter SG, Endres JR. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010;11:15.
157. Shenderov BA. Probiotic (symbiotic) bacterial languages. Anaerobe 2011; in press.
158. Maslowski KM, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282-1286.
159. Russell WR, et al. Anti-inflammatory implications of the microbial transformation of dietary phenolic compounds. Nutr Cancer 2008;60:636-642.
160. Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. Cell Microbiol 2011;13:670-676.
161. Pukatzki S, et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system. Proc Natl Acad Sci USA 2006;103:1528-1533.
162. Shrivastava S, Mande SS. Identification and functional characterization of gene components of Type VI Secretion system in bacterial genomes. PLoS ONE 2008;3:e2955.
163. Foligne B, et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007;133:862-874.
164. Raghavan V, Groisman EA. Orphan and hybrid two-component system proteins in health and disease. Curr Opin Microbiol 2010;13:226-231.
165. Sonnenburg ED, Sonnenburg JL, Manchester JK, Hansen EE, Chiang HC, Gordon JI. A hybrid two-component system protein of a prominent human gut symbiont couples glycan sensing in vivo to carbohydrate metabolism. Proc Natl Acad Sci USA 2006;103:8834-8839.
166. Ege MJ, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364:701-709.
167. Chen Y, Blaser MJ. Farm microbiome and childhood asthma. N Engl J Med 2011;364:1972-1973; author reply 1973.
168. Blaser MJ. Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology 2010;139:1819-1822.
169. Duan J, Kasper DL. Regulation of T cells by gut commensal microbiota. Curr Opin Rheumatol 2011;23:372-376.
170. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
171. Waterman M, et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis 2011;17:1936-1942.
172. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
173. Biswas A, Petnicki-Ocwieja T, Kobayashi KS. Nod2: a key regulator linking microbiota to intestinal mucosal immunity. J Mol Med (Berl) 2011; in press.
174. Matmati M, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011;43:908-912.
175. Martin F, Dixit VM. A20 edits ubiquitin and autoimmune paradigms. Nat Genet 2011;43:822-823.
176. Musone SL, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011;12:176-182.
177. Rowland I, et al. Current level of consensus on probiotic science - report of an expert meeting - London, 23 November 2009. Gut Microbes 2010;1:436-439.
178. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-115.
179. Marteau PR. Probiotics in clinical conditions. Clin Rev Allergy Immunol 2002; 22:255-273.
180. Mercer M, et al. How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol 2011; in press.
181. Bibiloni R, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100:1539-1546.
182. Tursi A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-2227.
183. Gionchetti P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
184. Mimura T, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114.
185. Cabre E, A Gassull M. Probiotics for preventing relapse or recurrence in Crohn's disease involving the ileum: are there reasons for failure? J Crohns Colitis 2007;1:47-52.
186. Uronis JM, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 2011;17:289-297.
187. Reiff C, et al. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1721-1736.
188. Steidler L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
189. Dusko Ehrlich S, MetaHIT consortium. Metagenomics of the intestinal microbiota: potential applications. Gastroenterol Clin Biol 2010;34(Suppl):S23-S28.
190. Shanahan F. Gut microbes: from bugs to drugs. Am J Gastroenterol 2010;105:275-279.